Product Datasheet

GLS2 Antibody - BSA Free NBP1-76544

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 8

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP1-76544

Updated 9/9/2025 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP1-76544



NBP1-76544

GLS2 Antibody - BSA Free

GLS2 Antibody - BSA Free	
Product Information	
Unit Size	0.1 mg
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS
Target Molecular Weight	66 kDa
Product Description	
Description	Novus Biologicals Rabbit GLS2 Antibody - BSA Free (NBP1-76544) is a polyclonal antibody validated for use in IHC, WB, ELISA, ICC/IF and Simple Western. Anti-GLS2 Antibody: Cited in 8 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	27165
Gene Symbol	GLS2
Species	Human, Mouse, Rat
Reactivity Notes	Use in Human reported in scientific literature (PMID:33799686).
Specificity/Sensitivity	Specificity for GLS2 versus GLS1 has not been determined.
Immunogen	Antibody was raised against a 18 amino acid peptide near the center terminus of human GLS2 (NP_037399).
Product Application Details	
Applications	Western Blot, Simple Western, Immunohistochemistry-Paraffin, ELISA, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry
Recommended Dilutions	Western Blot 0.5-1 ug/ml, Simple Western 1:100, ELISA 1:100-1:2000, Immunohistochemistry 5 ug/ml, Immunocytochemistry/ Immunofluorescence 20 ug/mL, Immunohistochemistry-Paraffin 5 ug/ml
Application Notes	In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. See <u>Simple Western Antibody Database</u> for Simple Western validation: Tested in Hek293 lysate 0.5 mg/mL, separated by Size, antibody dilution of 1:100, apparent MW was 60 kDa. Separated by Size-Wes, Sally Sue/Peggy Sue. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.



Images

Western Blot: GLS2 Antibody [NBP1-76544] - Glutaminase protein expression in PC3 and PC3M cell lines before/after CB-839 treatment. PC3 & PC3M cells were treated (+) or not treated (-) with GLS1 inhibitor CB-839 (1 uM) and their expression of GLS1 & GLS2 proteins determined by Western blot. Antibodies specific for GAC & KCA were utilized on two replicate samples, while GLS2 expression was determined on three. PC3 cell lysates expressed GLS2 more than PC3M cell lysates regardless of CB-839 treatment. The difference in GLS2 expression was significant in the untreated cells (P?<?0.03) but because of high variability the difference was not significant in the drug-treated cells. Levels of GLS1 (GAC and KGA) were similar in all cell lysates. Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/s41598-017-16327-z), licensed under a CC-BY license.

PC3 PC3M

PC3 PC3M

PC3 PC3M


ACA GAC
β-actin

CGLS2 Expression Quantified


Average density

Average density

Immunocytochemistry/Immunofluorescence: GLS2 Antibody [NBP1-76544] - of GLS2 in Human Kidney cells. Dilution 20 ug/mL.



Immunohistochemistry: GLS2 Antibody [NBP1-76544] - Immunohistochemistry of GLS2 in human kidney tissue with GLS2 antibody at 5 ug/mL.




Simple Western: GLS2 Antibody [NBP1-76544] - Simple Western lane view shows a specific band for GLS2 in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.



Immunocytochemistry/ Immunofluorescence: GLS2 Antibody - BSA Free [NBP1-76544] - Histological analyses for assessing response to bevacizumab treatment. A Immunofluorescence staining of tumor vasculature & integrin β3 with antibodies against CD31 (green) & CD61 (integrin β3, red) in the treated & control groups at the end of the study. B Quantitative analysis of integrin β3 & CD31-positive area fraction of tumors between the control & treatment groups. **P < 0.05.

Magnification: ×200. Microvascular density (CD31) from the therapy group (C) & control group (D). Tumor cell proliferation (Ki-67) from the therapy group (F) & control group. Error bars denote standard errors, Mann–Whitney U-test were applied, **P < 0.05. Magnification: ×200 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31604441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Cavino K, Sung B, Su Q, Na E et Al. Glucagon Receptor Inhibition Reduces Hyperammonemia and Lethality in Male Mice with Urea Cycle Disorder Endocrinology 2020-11-18 [PMID: 33206168]

Emmanuel Benichou, Bolaji Seffou, Selin Topçu, Ophélie Renoult, Véronique Lenoir, Julien Planchais, Caroline Bonner, Catherine Postic, Carina Prip-Buus, Claire Pecqueur, Sandra Guilmeau, Marie-Clotilde Alves-Guerra, Renaud Dentin The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolism Nature Communications 2024-02-29 [PMID: 38424041]

Arenas YM, Felipo V Sustained Hyperammonemia Activates NF-?B in Purkinje Neurons Through Activation of the TrkB-Pl3K-AKT Pathway by Microglia-Derived BDNF in a Rat Model of Minimal Hepatic Encephalopathy Molecular neurobiology 2023-02-15 [PMID: 36790604] (Western Blot)

Mao X, Chen H, Lin A et al. Glutaminase 2 Knockdown Reduces Hyperammonemia and Associated Lethality of Urea Cycle Disorder Mouse Model Journal of inherited metabolic disease 2022-01-06 [PMID: 34988999] (WB, Mouse)

Zacharias N, Wang L, Maity T et al. Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo International Journal of Molecular Sciences 2021-03-11 [PMID: 33799686] (WB, Human)

Wang Y, Liu H, Yao D et al. 18F-labeled magnetic nanoparticles for monitoring anti-angiogenic therapeutic effects in breast cancer xenografts J Nanobiotechnology 2019-10-11 [PMID: 31604441] (IHC-P, Mouse)

Zacharias NM, McCullough C, Shanmugavelandy S et al. Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer Sci Rep. 2017-11-23 [PMID: 29170516] (WB, Human)

Gross MI, Demo SD, Dennison JB et al. Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer. Mol. Cancer Ther. 2014-02-13 [PMID: 24523301] (WB, Human)





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966

nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449

Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com

Technical Support: nb-technical@bio-

techne.com

Orders: nb-customerservice@bio-techne.com

General: novus@novusbio.com

Products Related to NBP1-76544

NBP1-76544PEP-0.1mg GLS2 Antibody Blocking Peptide

HAF008 Goat anti-Rabbit IgG Secondary Antibody [HRP]

NB7160 Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]

NBP2-24891 Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-76544

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

